Skip to content

Effects of a Gum Gel Intended to Treat Signs and Symptoms of Teething

Retrospective Analysis of the Effects of a Gum Gel Intended to Treat Signs and Symptoms of Teething in Infants

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04879836
Enrollment
51
Registered
2021-05-10
Start date
2018-12-01
Completion date
2019-06-30
Last updated
2021-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tooth Eruption Disorder

Keywords

gums, redness, fever, paediatric, inappetence, sleep disturbance

Brief summary

Teething discomfort is a widespread disorder affecting a very high percentage of infants. The use of hyaluronic acid gels has been shown in the last 20 years to be an effective tool, generally devoid of side effects, in reducing oral mucosal inflammation in adults. Its effectiveness in infants is affected by the strength of hyaluronic acid retention over the oral mucosa. This is in turn affected by formulation and may vary between different products due to the different ingredients used. In this study, the results collected by monitoring the paediatric experience regarding a newly developed HA-based medical device, intended to counteract teething discomfort in infants, will be reported.

Interventions

DEVICETeething Gel

Dosage: application of an even coat of 1mm thickness Frequency: 5 times/day (after main meals and before sleeping) Duration: 4 weeks

DEVICETeething Ring

The teething ring was filled with a coolant Usage: 5/10 min per time Frequency: 5 times/day Duration: 4 weeks

Sponsors

University of Urbino Carlo Bo
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Months to 12 Months
Healthy volunteers
No

Inclusion criteria

* Teething discomfort * Being healthy (except for teething discomfort)

Exclusion criteria

* Being placed on one of the following therapies in the 45 days prior to the beginning of the study: immunosuppressive, cytotoxic, cortisone, antibiotics, antifungal and hormone therapy

Design outcomes

Primary

MeasureTime frameDescription
Unexplained cry1 month (1 check per week)5-level Likert scale completed by the paediatrician
Irritability1 month (1 check per week)5-level Likert scale completed by the paediatrician
Sleep disturbance1 month (1 check per week)5-level Likert scale completed by the paediatrician
Inappetence1 month (1 check per week)5-level Likert scale completed by the paediatrician
Salivation1 month (1 check per week)5-level Likert scale completed by the paediatrician
Gum redness1 month (1 check per week)5-level Likert scale completed by the paediatrician
Fever1 month (1 check per week)Number of days with fever
General well-being1 month (1 check per week)5-level Likert scale completed by the paediatrician

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026